Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University